DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Papp KA, Langley RG, Lebwohl M. et al.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Lancet (London, England) 2008;
371: 1675-1684
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.